Sonoma Pharmaceuticals, which develops treatments for dermatological conditions and advanced wound care with its flagship product stabilized hypochlorous acid, saw its stock plunge almost 20% on Friday, August 9. The losses followed the release of worse than expected quarterly financial results. Details Sonoma stock fell 19.7% on Friday to $0.25…